Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | IGLV6-57 | P01721 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591555 | 0.88 | KCNA5 (0.40) | KCNA5KCNJ5KCNJ3IGLV6-57KDM4E | |
| SCHEMBL21592245 | 0.87 | KCNA5 (0.38) | KCNA5KCNJ5KCNJ3IGLV6-57 | |
| SCHEMBL21591526 | 0.86 | PDE3B (0.39) | KCNA5KCNJ5KCNJ3IGLV6-57KDM4E | |
| SCHEMBL21591520 | 0.80 | HDAC3 (0.41) | KCNA5KCNJ5KCNJ3IGLV6-57KDM4E | |
| SCHEMBL21591510 | 0.80 | PRKDC (0.38) | KCNA5KCNJ5KCNJ3IGLV6-57 | |
| SCHEMBL21591460 | 0.79 | KCNA5 (0.40) | KCNA5KCNJ5KCNJ3IGLV6-57 | |
| SCHEMBL21592277 | 0.75 | KCNA5 (0.39) | KCNA5KCNJ5KCNJ3KDM4EMEN1 | |
| SCHEMBL21592279 | 0.74 | KCNA5 (0.44) | KCNA5KCNJ5KCNJ3IGLV6-57KDM4E | |
| SCHEMBL21591552 | 0.74 | KCNA5 (0.41) | KCNA5KCNJ5KCNJ3IGLV6-57KDM4E | |
| SCHEMBL21591500 | 0.69 | HDAC3 (0.41) | KCNA5KCNJ5KCNJ3IGLV6-57KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| EP-3807264-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | GPR119 1162/4885KCNA5 2592/4885KCNJ5 1509/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | GPR119 1162/4885KCNA5 2592/4885KCNJ5 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.